A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption - 07/08/11
Reprint requests: Allan C. Halpern, MD, MS, Dermatology Service, Memorial Sloan-Kettering Cancer Center, 160 E 53 St, New York, NY 10022.Abstract |
Background |
Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking.
Objective |
We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash.
Methods |
In all, 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face. At baseline, week 2, and week 5, a dermatologist performed facial lesion counts, patients reported perceived severity of rash-related symptoms, and standardized facial photographs were obtained for blinded evaluation of global rash severity.
Results |
Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 (P < .001) and 5 (P = .02). However, there were no significant differences in patients’ assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides.
Limitations |
This study was not placebo controlled.
Conclusions |
Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash.
Le texte complet de cet article est disponible en PDF.Key words : acne-like rash, cetuximab, clinical trial, pimecrolimus
Plan
| Supported by an investigator-initiated grant from Bristol-Myers Squibb and ImClone Systems Inc. |
|
| Disclosure: Dr Saltz is a compensated consultant for ImClone, Genentech, Roche, Alchemia, YM Bioscience, Merck, Pfizer, and Bristol-Myers Squibb, and has funded research from Bristol-Myers Squibb, ImClone, Genentech, Roche, Pfizer, Merck, and Taiho. Dr Halpern received honoraria and research funding from Bristol-Myers Squibb. Mr Dusza owns stock of Bristol-Myers Squibb. Drs Scope, Lieb, and Myskowski and Ms Phelan have no conflicts of interest to declare. |
Vol 61 - N° 4
P. 614-620 - octobre 2009 Retour au numéro
Article précédent
- What’s New Online?
- Foot or hand malformations related to deep venous system anomalies of the lower limb in Klippel-Trénaunay syndrome
- Pedro Redondo, Gorka Bastarrika, Leyre Aguado, Antonio Martínez-Cuesta, Alejandro Sierra, Juan Cabrera, Alberto Alonso-Burgos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?